NASA's Juno probe unexpectedly shuts down briefly en route to Jupiter

Posted on by

NASA's Juno probe takes one last swing past Earth to pick up energy for the five-year trip to Jupiter. It's not clear what impact a 20-minute lapse into 'safe mode' had on the mission.

NASA's Juno spacecraft buzzed Earth on Wednesday to enter the final leg of its 1.74-billion-mile trip to Jupiter but not without giving mission managers an adrenaline rush as it sped on its way.

Subscribe Today to the Monitor

Click Here for your FREE 30 DAYS of The Christian Science Monitor Weekly Digital Edition

The craft, launched in August 2011, is slated to arrive at Jupiter in early July 2016. It flitted past Earth some 347 miles above the planet's surface Wednesday, taking advantage of Earth's gravity to put it on the right trajectory and give it the final burst of energy it needed to complete the five-year trip.

But 10 minutes after its close encounter with Earth, Juno unexpectedly shut down all nonessential systems. The condition, known as safe mode, occurred when Earth eclipsed the sun from Juno's perspective for about 20 minutes. This deprived the spacecraft of power from its solar panels. As designed, the craft quickly switched to battery power. But Juno also entered safe mode.

At this point, it's unclear what impact this has had on plans to use the Earth flyby to adjust the science instruments on the craft a brief throat-clearing for the research tools that underpin this $1.1 billion mission. Some 29 sensors channel data into nine instruments.

During the flyby, the craft was to have snapped images of Earth and atmospheric conditions willing was to have received a repeated "Hi" in Morse code from amateur-radio operators around the world.

Safe mode still allows the craft to communicate with the ground and provide data on the status of its systems. So far, the craft looks healthy, according to Guy Webster, a spokesman for NASA's Jet Propulsion Laboratory in Pasadena, Calif. The JPL is overseeing mission operations.

Mission controllers are still downloading engineering data as well as the images Juno took of Earth during the flyby. Once the data are in hand, engineers will pore over it for clues to Juno's glitch.

Read the original here:

NASA's Juno probe unexpectedly shuts down briefly en route to Jupiter

Governor announces nanotechnology hub, $1.5 billion investment in SUNY IT Marcy campus

Posted on by

Governor announces nanotechnology hub in Marcy /Courtesy: Jim Kenyon

MARCY, ONEIDA CO. -- Governor Andrew Cuomo came to the SUNY IT campus in Marcy Thursday to announce the creation of Nano Utica.

The governor announced that six global technology companies intend to invest $1.5 billion to create the state's second major hub of nanotechnology research and development.

The governor says thepublic-private partnership will create more than 1,000 high-tech jobs on the campus of SUNY IT. Among the companies involved are Sematech, Advanced Nanotechnology Solutions Inc. (ANSI), IBM, Lam Research and Tokyo Electron. The governor said, "The new Nano Utica facility will serve as a clean room and research hub for Nano Utica whose members can tap into the training here at SUNY IT and local workforce putting the Mohawk Valley on the map as an international location for nanotechnology research and development."

The computer chip packaging consortium will work inside a complex which is now under construction on the SUNY IT campus due to open in late 2014.

Visit link:

Governor announces nanotechnology hub, $1.5 billion investment in SUNY IT Marcy campus

There Is No Nanotechnology Equivalent to the Digital Divide

Posted on by

A recent article in the venerable Financial Timesproposed a sort of nanotechnology equivalent to theoft-mentioned digital divide(the idea thatthe benefits of digital technology appear to accrue to the wealthy while the poor are left out). At issue in the articleis whether developed economies and poorer nations are separated in their respective access to nanotechnology.

So, is there a nanotech divide?

The answer probably lies somewhere between yes and no, depending on the metric you use. But I would argue that nanotechnology has been one of the most egalitarian fields in technology history.

First, you can look at where the money goes. On this count, nanotechnology is basically the same as any other emerging technology: the initial targeted applications are those that can sustain the price premium for using a new and expensive technology.

However, nanomaterials can already be found in inexpensive items ranging from odor-resistant socks to plastic beer bottles. So as the manufacturing technologies have matured and ramped up, we have seen prices fall and the democratization of nano-enabled products spread.

But I've often argued that analyzing nanotech's impact purely on economic terms can be misleading. It is usually a stretch to try to draw parallels between an emerging technology like nanotech and a developed field like information technology. Nanotech is still in its commercial infancy.

Instead, let's focus just on nanotechnology research, which constitutes the bulk of the activity in the field today. With nanotech, we are probably witnessing the most democratic and open-access research ever in a new technology.

Every day, articles along every conceivable line of nanotech research are publishedand made available on the web, with an increasing number of articles being published with open access to everyone. If there remains a divide here, it stems from a digital dividenot from nanotech itself.

We see this open access play out in the way that most research is now conducted: through international research groups working in cooperation with each other. This has actually been proven through quantitative analysis. Nanotechnology research is international and depends on cross-border cooperation if it is to succeed. Granted, most of this research goes on in developed nations, but not exclusivelyover 35 countries have announced funding for nanotechnology initiatives.

Finally, you can look at who's benefitting from nanotechnoloy. On that front, their are numerous projects that target developing countries, like improved membranes for creating clean drinking waterand systems tosterilize medical equipment in remote regions of the world. In fact, I am hard pressed to think of an emerging technology in which so much of its R&D and its financial backers are so heavily invested in making an impact in the developing world.

View post:

There Is No Nanotechnology Equivalent to the Digital Divide

Increased R&D Interest to Drive the Global Market for Nanotechnology in Drug Delivery, According to a Soon to be …

Posted on by

San Jose, California (PRWEB) October 11, 2013

Follow us on LinkedIn GIA invites senior industry executives, domain experts, technologists and market strategists to participate in a comprehensive global research initiative studying the market for Nanotechnology in Drug Delivery. The study will examine key drivers and trends impacting the market such as technology developments in drug delivery nanosystems; expanding nanotechnology applications in nasal, oral and epidermal drug delivery routes; heavy R&D investments and development of novel nanocarriers; breakthrough developments in the concept of Clever drug targeting systems.

An important sector of the Nanomedicine industry, Nanotechnology in Drug Delivery is defined as the application of nanotechnology in drug delivery. Nano Drug Delivery techniques involve encapsulation of nano size particles of drugs in polymer matrices that have targeting ligands that bind to diseased cells for controlled release of drugs. Key benefits of nano drug delivery systems triggering R&D interests include targeted and accurate intracellular delivery of drugs and reduced immune system response and resulting side effects; sustained and controlled release of drugs for optimum clinical impact and patient outcome; and superior retention of bioactivity of drugs by protecting them from environmental degradation. Promising areas of nanodrug delivery systems which are expected to witness the maximum impact in terms of investor interest and market opportunities include injectable drugs, oral drugs, implantable drug delivery systems, external topical delivery, and transdermal delivery, among others.

The upcoming years are expected to witness nanodrug delivery systems expand to include drug compounds for cancer and infectious diseases. R&D efforts are already underway to develop ethylene glycol molecules based nanoparticles capable of transporting chemotherapy drugs directly to tumour cells. Another key breakthrough in the oncology field is the development of nanosponge drug delivery system capable of significantly reducing tumour growth as compared to conventional injectable drugs. Cardiology also represents a promising area with studies underway to develop nanoparticles to deliver clot busting drugs. In this regard, iron oxide based nanoparticles are being researched for their ability to deliver drugs directly to stents implanted within the arteries.

A key factor fuelling R&D investments in nanodrug delivery systems is the growing pressure on pharmaceutical companies to develop breakthrough novel next generation drugs against a backdrop of intense competition from generics as most second generation drugs continue to lose patents. Also the aging world population is pushing up unmet medical needs among the elderly creating an urgent need for novel and effective therapies. The paradigm shift of the pharma industry towards personalized medicine will additionally lend traction to nanotechnology-enabled drug delivery therapies that target the molecular cause of the disease. Poised to gain in the future are delivery systems that enable individualized pharmacotyping and patient specific delivery of drugs. The study estimates Nanotechnology in Drug Delivery to be a multi-million dollar market worldwide, while more precise market-size and growth projections will be made available during the 2nd stage of report preparation, and data analysis.

The research and analyses will be released shortly in the form of a comprehensive research report. The report by design, will attempt to provide exhaustive analysis, data, trends, market share, market size, statistics, forecasts and competitive intelligence. The report is modeled to offer precise and unbiased, actionable market insights including in-depth segmentation of market sub-sectors, demand estimates and projections and analysis of trends in each of the sectors, identification of leading players, and the competitive structure, among others.

Developed for Drug Developers/Manufacturers, Strategic Planners, Business Development Executives, Management Consultants, Investment Bankers, Consulting Firms, Marketing & Sales Executives, C-Level Decision Makers, Market Strategists and Technology Domain Experts, the report helps identify the biggest opportunities in this space and offers accurate latent demand forecasting that empowers quantitative decision making among existing market players and new entrants.

For more details about how you can participate, please click here.

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Read the original:

Increased R&D Interest to Drive the Global Market for Nanotechnology in Drug Delivery, According to a Soon to be ...

Jewish-Americans James Rothman and Randy Schekman share 2013 Nobel Prize for Medicine – Video

Posted on by


Jewish-Americans James Rothman and Randy Schekman share 2013 Nobel Prize for Medicine
Jewish-Americans James Rothman and Randy Schekman, along with German-born researcher Thomas Suedhof, have been named the winners of the 2013 Nobel Prize for ...

By: JewishNewsOne

Read the original:

Jewish-Americans James Rothman and Randy Schekman share 2013 Nobel Prize for Medicine - Video

"I danced around" – Interview with Randy W. Schekman, 2013 Nobel Laureate in Physiology or Medicine – Video

Posted on by


"I danced around" - Interview with Randy W. Schekman, 2013 Nobel Laureate in Physiology or Medicine
Telephone interview with Randy W. Schekman following the announcement of the 2013 Nobel Prize in Physiology or Medicine. The interviewer is Nobelprize.org #39;s ...

By: Nobel Prize

See more here:

"I danced around" - Interview with Randy W. Schekman, 2013 Nobel Laureate in Physiology or Medicine - Video

International Space Medicine Summit 2013 — Panel I: History of Long-duration Spaceflights (Rus) – Video

Posted on by


International Space Medicine Summit 2013 -- Panel I: History of Long-duration Spaceflights (Rus)
May 17, 2013 Physicians and biomedical scientists gather to discuss space medicine research at this annual conference organized by the Baker Institute and Ba...

By: BakerInstitute

Read more here:

International Space Medicine Summit 2013 -- Panel I: History of Long-duration Spaceflights (Rus) - Video

International Space Medicine Summit 2013 — Panel II: Planning for Long-duration Missions (Rus) – Video

Posted on by


International Space Medicine Summit 2013 -- Panel II: Planning for Long-duration Missions (Rus)
May 17, 2013 Physicians and biomedical scientists gather to discuss space medicine research at this annual conference organized by the Baker Institute and Ba...

By: BakerInstitute

Read more:

International Space Medicine Summit 2013 -- Panel II: Planning for Long-duration Missions (Rus) - Video

International Space Medicine Summit 2013 — Panel III: Maximizing Scientific Return (Rus) – Video

Posted on by


International Space Medicine Summit 2013 -- Panel III: Maximizing Scientific Return (Rus)
May 17, 2013 Physicians and biomedical scientists gather to discuss space medicine research at this annual conference organized by the Baker Institute and Ba...

By: BakerInstitute

Read the original:

International Space Medicine Summit 2013 -- Panel III: Maximizing Scientific Return (Rus) - Video

Michael Caridi Awarded Honorary Doctorate From College of Podiatric Medicine

Posted on by

NEW YORK, NY--(Marketwired - Oct 11, 2013) - In 2003 Michael Caridi was awarded with the prestigious honorary doctorate for his contribution and support of Podiatric medicine and the city of Harlem. Michael Caridi today continues his efforts to see Harlem's economy grow.

"I'm very proud to have received this award from such an esteemed college which is one of the oldest podiatric colleges in the country," said Michel Caridi. He went on to say, "Supporting academic institutions like this is crucial for future of our youth and our country. It helps move our country forward, and keeps the door open to obtain the American Dream. God bless America."

About College of Podiatric Medicine:

Located in the City of New York, the College had its first home at 125th Street and rapidly outgrew its quarters. Three successive moves culminated in the erection in 1927 of the present College building dedicated to podiatric medical education and clinical training.

Completed in 1978, the new facility, the Foot Center of New York, provides clinical services to the community and continues to be affiliated with the College. The largest center of its kind, the Foot Center of New York ministers to a wide and diverse patient load in more than 25,000 patient visits annually.

The College has recently completed a series of renovations that have brought its classrooms and labs to the leading edge of medical education technology.A new Anatomy Lab and a new Clinical Skills Lab, as well as fully renovated classrooms, computer rooms, study areas and other College facilities, enable students to work in an environment optimized for learning and for study.

NYCPM is affiliated with a number of leading medical institutions in the New York City area, including the Columbia University College of Physicians & Surgeons, Harlem Hospital Center, Lincoln Medical & Mental Health Center, Long Island College Hospital, Metropolitan Hospital Center, Nassau University Medical Center, the New York-Presbyterian Healthcare System, and Parker Jewish Institute for Health Care and Rehabilitation.These affiliations provide additional outstanding educational and clinical opportunities for NYCPM's students.

About Michael Caridi Michael Caridi was born in Brooklyn and raised in Catskill, NY. He currently resides in Greenwich, Connecticut and has offices in Mid-town Manhattan, New York, NY. He is married and has four children. A graduate of St. John's University, Michael Caridi obtained a Bachelor of Science degree in Accounting and Business Administration.Michael Caridi's business endeavors span various industries. He is currently Managing Director of Seahawk Capital Partners which specializes in business development & consulting, mainly in the BioTech Industry.Michael Caridi is Chairman of MAJIC Development Group LLC, and has been involved in several significant development projects, as well as construction for many Fortune 500 clients and retailers. Among Michael Caridi's most notable achievements are: lease acquisition, obtaining the air rights, and negotiation of the sale of Harlem Park, a mixeduse project in Harlem, NYC; the lease acquisition, financing, gutting and fullscale rehab of the 600room Holiday Inn Hotel on West 57th Street in Manhattan; the acquisition, financing and construction of a 204unit, $70 million condominium and rental complex in Palisades Park, New Jersey; and the acquisition, renovation and sale of 96 coop apartments in Long Beach, NY.Other recent projects include involvement in an Italian Cosmetic Wipe company, an ecofriendly plastics and electronics company that had products in 70,000 retail stores, and a diverse mix of independent business ventures including residential and commercial propertyownership, restaurant owner, mortgage banking, ship salvaging and dismantling, hotel ownership and development, security services, magazine publishing, and alcohol/nonalcoholic import and export.

Michael Caridi's philanthropic efforts have rivaled those of his business successes. In the past he has served on the Board of Directors of the Coalition of Italian American Associations; the Republican Leadership Council; The Forum Club; The National Ethnic and Charitable Organization; and The Italo American Foundation. Michael Caridi is a proud member of the Lumen Institute, and supporter of the New York City Police Foundation and C.O.R. E. (Congress of Racial Equality).

Michael Caridi Awards and Honors:

Here is the original post:

Michael Caridi Awarded Honorary Doctorate From College of Podiatric Medicine